Stockscreener 앱 받기
18.79
2.06%
0.38
시간 외 거래:
18.79
Bicara Therapeutics Inc 주식(BCAX)의 최신 뉴스
[144] Bicara Therapeutics Inc. SEC Filing - Stock Titan
Bicara Therapeutics Inc. exposes urgent need for improved therapies in HPV negative recurrent HNSCC - Traders Union
Cantor Fitzgerald L. P. Takes $1.58 Million Position in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Affiliate plans to sell 6,499 BCAX shares (NASDAQ: BCAX) - Stock Titan
Aug Sentiment: How much upside does Bicara Therapeutics Inc have2026 Key Highlights & High Win Rate Trade Alerts - baoquankhu1.vn
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock - MarketBeat
Bicara Therapeutics (BCAX) president sells $245,713 in stock - Investing.com
Bicara Therapeutics (BCAX) COO exercises options and sells shares - Stock Titan
Bicara Therapeutics Inc. targets tumor microenvironment with combined EGFR and TGF beta inhibition - Traders Union
Cantor Fitzgerald L. P. Invests $1.58 Million in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference - MarketBeat
Bicara Therapeutics stock hits 52-week high at 19.72 USD By Investing.com - Investing.com Nigeria
Claire Mazumdar Sells 36,766 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock - MarketBeat
Bicara Therapeutics CEO Sells Shares - TradingView
Bicara Therapeutics (NASDAQ: BCAX) CEO exercises options, sells 36,766 shares - Stock Titan
Bicara Therapeutics (BCAX) Is Up 11.9% After US$172.5 Million Equity Raise And CEO Share Sale - simplywall.st
United StatesGoodwin Advises Bicara Therapeutics On Closing Of $172.5 Million Oversubscribed Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares - Mondaq
Bicara Therapeutics Inc. targets fibrotic tumor barriers in HPV negative R M HNSCC - Traders Union
Bicara Therapeutics stock hits 52-week high at 19.72 USD - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After FICERA Data And Capital Raise - simplywall.st
Stock Report: Can Bicara Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Drop Watch & Intraday High Probability Setup Alerts - Naître et grandir
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan - Yahoo Finance
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Bicara Therapeuti - GuruFocus
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock - Investing.com UK
Aug Sectors: How is Bicara Therapeutics Inc managing supply chain issuesMarket Volume Report & High Conviction Investment Ideas - baoquankhu1.vn
Bicara Therapeutics CEO Mazumdar sells $154k in BCAX stock By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $49,278.63 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $33,469.64 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares - MarketBeat
Bicara Therapeutics (BCAX) CEO exercises options and sells 8,234 shares - Stock Titan
Fundamentals Check: How cyclical is Bicara Therapeutics Incs revenue streamWeekly Risk Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference - Yahoo Finance
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 16,300 Shares of Stock - MarketBeat
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $54,074.75 in Stock - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 17,392 Shares - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) CFO Ivan Hyep Sells 13,555 Shares - MarketBeat
Cohlhepp, Bicara Therapeutics president, sells $315k in shares By Investing.com - Investing.com Australia
Cohlhepp, Bicara Therapeutics president, sells $315k in shares - Investing.com Australia
Planned Bicara (BCAX) insider sale: 17,392 shares under 10b5-1 - Stock Titan
Bicara Therapeutics Inc builds enduring patient trust - Traders Union
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Bitget
BCAX (Nasdaq) insider sale: 16,300 shares via option exercise (03/04/2026) - Stock Titan
Why Bicara Therapeutics (BCAX) Is Up 10.3% After US$150 Million Follow-On Offering For Lead Drug - simplywall.st
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BCAX (NASDAQ) insider to sell 13,555 shares after option exercise - Stock Titan
Ryan Cohlhepp sells BCAX shares; Form 144 shows trades (BCAX) - Stock Titan
BCAX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Will Bicara Therapeutics Inc benefit from rate cuts2025 Performance Recap & Daily Profit Maximizing Tips - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):